Skip to main content

Table 10 The scores of SF-36 in the 24-month period

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group \( \overline{x}\pm S \) t P
The treatment group 67.72 ± 6.06 −0.397 0.691
The control group 67.47 ± 5.53